Akeso shares fall over 24% after US application for ivonescimab is not approved
康方生物跌超24%,此前康方生物肿瘤免疫治疗药物依沃西在美国的首次上市申请未获得批准。
The US setback hits one of Hong Kong's most closely watched biotech names.
Hong Kong-listed biotech Akeso fell more than 24% on Nov 16 after the first US marketing application for its tumour immunotherapy drug ivonescimab was not approved, according to Wallstreetcn.